Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet

@article{Halimi2008CombinationTI,
  title={Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet},
  author={Serge Halimi and Anja Schweizer and B Mini{\'c} and James E Foley and Sylvie Dejager},
  journal={Vascular Health and Risk Management},
  year={2008},
  volume={4},
  pages={481 - 492}
}
Vildagliptin is a potent and selective inhibitor of dipeptidyl peptidase-IV (DPP-4), orally active, that improves glycemic control in patients with type 2 diabetes (T2DM) primarily by enhancing pancreatic (α and β) islet function. Thus vildagliptin has been shown both to improve insulin secretion and to suppress the inappropriate glucagon secretion seen in patients with T2DM. Vildagliptin reduces HbA1c when given as monotherapy, without weight gain and with minimal hypoglycemia, or in… Expand
Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus
TLDR
An overview of the clinical results of combination therapy with metformin and the DPP-4 inhibitor vildagliptin in T2DM patients is provided and data available suggest that administration of fixed-dose combination products may improve compliance and adherence of patients to therapy, resulting in an improved metabolic control. Expand
Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus
TLDR
Oral vildagliptin was generally well tolerated in patients with type 2 diabetes, was weight neutral and was associated with a low risk of hypoglycaemia, reflecting its glucose-dependent mechanism of action. Expand
Drug evaluation: Vildagliptin-metformin single-tablet combination
TLDR
Available data support the use of vildagliptin in combination with metformin as a promising second-line treatment for the management of type 2 diabetes and this is reflected in the latest UK National Institute for Health and Clinical Excellence draft guideline for consultation on new agents for blood glucose control in type 1 diabetes. Expand
Saxagliptin plus metformin combination therapy
  • A. Scheen
  • Medicine
  • Expert review of endocrinology & metabolism
  • 2012
Metformin is considered to be the first-line drug therapy for the management of Type 2 diabetes. Incretin-based therapies, and especially dipeptidyl peptidase-4 inhibitors, offer new opportunitiesExpand
The Old and the New in the Treatment of Type 2 Diabetes: Focus on the Combination Therapy with Dipeptidyl Peptidase-4 Inhibitors and Metformin:
TLDR
This commentary will focus on the role of new oral agents influencing the incretin system and the putative advantages of their co-administration with metformin, an old, effective anti-hyperglycemic agent also able to exert beneficial actions on arterial vessels, reducing the risk of macrovascular-related events. Expand
Randomised cross-over trial of vildagliptin and pioglitazone as add-on therapy in patients with type 2 diabetes: predicting Which One is Right Here (WORTH) study protocol
TLDR
This study tested whether glycaemic response to representative treatments of dipeptidyl peptidase-4 inhibitors (vildagliptin) and thiazolidinediones (pioglitazone) varies according to ethnicity, gender, baseline obesity, triglyceride level or genetic variation. Expand
Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment
  • A. Scheen
  • Medicine
  • Expert opinion on drug metabolism & toxicology
  • 2012
TLDR
This review analyses the pro and contra of using a combination of saxagliptin and metformin (separately or as a fixed-dose combination) in type 2 diabetic patients with moderate or severe RI. Expand
Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study
  • L. Ji, C. Pan, +10 authors Lei Wang
  • Medicine
  • Cardiovascular Diabetology
  • 2013
TLDR
The VISION study will test the hypothesis that early use of combination therapy with vildagliptin and meetformin will provide good glycemic control and will be better tolerated than up-titration of metformin monotherapy, and correlate these benefits with age and BMI. Expand
Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin
  • A. Scheen
  • Medicine
  • Expert opinion on drug metabolism & toxicology
  • 2010
TLDR
The combination sitagliptin plus metformin may be used as a first- or second-line therapy in the management of type 2 diabetes, and improves blood glucose control more potently than either compound separately, without hypoglycemia and without increasing met formin-related gastrointestinal side effects. Expand
A COMPARISON OF THE EFFECTS OF COMBINATION VILDAGLIPTIN AND METFORMIN WITH VILDAGLIPTIN, METFORMIN MONOTHERAPY IN INDIAN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Objective To compare the effects of monotherapy using metformin, vildagliptin with combination of the metformin/vildagliptin agents on glycemic control (HbA1c and plasma glucose) and lipid profilesExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 124 REFERENCES
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
TLDR
Vildagliptin decreases HbA1c in patients whose type 2 diabetes is poorly controlled with high doses of insulin, and is also associated with reduced confirmed and severe hypoglycaemia. Expand
Measurements of Islet Function and Glucose Metabolism With the DPP-4 Inhibitor Vildagliptin in Patients With Type 2 Diabetes
TLDR
Vildagliptin improves islet function in T2DM and improves glucose metabolism in peripheral tissues and reduces fasting plasma glucose and postprandial glucose by 3-fold and 2-fold. Expand
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.
TLDR
Vildagliptin is an incretin degradation inhibitor that improves beta-cell function in diabetic patients by increasing the insulin secretory tone. Expand
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
TLDR
During the postprandial period, a single dose of vildagliptin reduced plasma glucose levels by enhancing suppression of EGP by augments insulin secretion and inhibits glucagon release, leading to enhanced suppression ofEGP. Expand
Pharmacokinetics and Pharmacodynamics of Vildagliptin in Patients with Type 2 Diabetes Mellitus
TLDR
Vildagliptin is likely to be a useful therapy for patients with type 2 diabetes based on the inhibition of DPP-4 and the subsequent increase in incretin hormones, GLP-1 and GIP, and the decrease in glucose and glucagon levels. Expand
On combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitors.
TLDR
Although the specific molecular target of metformin is still unknown, biguanides generally act to sensitize peripheral tissues to insulin action and inhibit hepatic gluconeogenesis and glycogenolysis, and DP IV inhibitors act to enhance the insulin response to a meal, via preservation of insulin sensitivity. Expand
The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves β-Cell Function and Insulin Sensitivity in Subjects With Impaired Fasting Glucose
TLDR
The DPP-4 inhibitor vildagliptin improves insulin sensitivity and β- cell function, leading to improved postprandial glycemia in subjects with IFG, who are known to have β-cell dysfunction. Expand
The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.
TLDR
The DPP-4 inhibitor vildagliptin improves insulin sensitivity and beta-cell function, leading to improved postprandial glycemia in subjects with IFG, who are known to haveBeta-cell dysfunction, and may prevent progression to diabetes in high-risk subjects. Expand
Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects*
TLDR
The data indicate that the rate and extent of absorption of vildagliptin and simvastatin were not affected when co-administered, nor was the metabolic conversion of simVastatin to its active metabolite altered. Expand
Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.
TLDR
Evidence is presented that DPP-4 inhibition by vildagliptin when added to metformin in type 2 diabetes over 52 weeks improves beta-cell function along with improved postmeal insulin sensitivity. Expand
...
1
2
3
4
5
...